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Novelty and Impact Statement: Scotland is uniquely placed to address the implications of 
HPV immunisation on cervical screening given (1) a national immunisation programme with 
very high uptake, (2) the ability to link immunisation with cervical screening data, (3) the 
existence of a national HPV sample archive. This study investigates how clinically validated 
HPV assays are affected by immunisation. This is both novel and timely, given the global move 




The management of cervical disease is changing worldwide as a result of HPV vaccination and 
the increasing use of HPV testing for cervical screening. However, the impact of vaccination 
on the performance of HPV based screening strategies is unknown. The SHEVa (Scottish HPV 
Prevalence in Vaccinated women) projects are designed to gain insight into the impact of 
vaccination on the performance of clinically validated HPV assays. Samples collated from 
women attending for first cervical smear who had been vaccinated as part of a national “catch 
up” programme were tested with three clinically validated HPV assays (2 DNA and 1 RNA). 
Overall HR-HPV and type specific positivity was assessed in total population and according to 
underlying cytology and compared to a demographically equivalent group of unvaccinated 
women.  HPV prevalence was significantly lower in vaccinated women and was influenced by 
assay-type, reducing by 23-25% for the DNA based assays and 32% for the RNA assay 
(p=0.0008). All assays showed over 75% reduction of HPV16 and/or 18 (p<0.0001) whereas 
the prevalence of non 16/18 HR-HPV was not significantly different in vaccinated vs 
unvaccinated women. In women with low grade abnormalities, the proportion associated with 
non 16/18 HR-HPV was significantly higher in vaccinated women (p<0.0001). Clinically 
validated HPV assays are affected differentially when applied to vaccinated women, dependent 
on assay chemistry. The increased proportion of non HPV16 /18 infections may have 
implications for clinical performance, consequently, longitudinal studies linking HPV status to 





HPV vaccination programmes have been implemented in several countries with success and 
their impact is now evident at the population level. Several ecological and direct linkage studies 
have shown significant associations between the reduction of vaccine-type HPV prevalence, 
associated disease and vaccination with both the bivalent and quadrivalent vaccines(1). 
Furthermore, there is encouraging evidence to suggest HPV-type cross-protective effect of the 
vaccines(2,3). 
We are at a crucial time for cervical disease management. In addition to vaccination 
programmes, there is now international consensus that HPV testing should replace cytology as 
the primary screening modality. Primary screening with HPV testing is predicated on several 
randomised control trials which demonstrate its superior sensitivity for the detection of CIN2+ 
over a longer time frame when compared to a single cytology screen(4). The demand and 
requirement for HPV testing is evident in the increasing range of assays, with varied chemistry, 
platform and typing capabilities, that are considered clinically validated for use in cervical 
screening(5).  
Epidemiology and surveillance studies designed to assess HPV type specific prevalence in 
vaccinated populations, provide limited insight into how clinically validated assays will 
perform in cervical screening. The assays used in surveillance studies typically have a high-
analytical sensitivity and broad spectrum genotyping capability and are not routinely used for 
cervical disease management. Comparatively, most clinically validated assays have been 
calibrated to clinical end points (CIN2+) and detect high-risk types only. There are very few 
studies which have applied clinically validated HPV assays to vaccinated cohorts. However, 
given that the reduction of HPV16 and/or 18 may lead to other high-risk (HR) HPV types 
becoming unmasked(6), potentially affecting the performance of validated assays, this should 
be addressed. 
Scotland has a population of 5.3 million people and an organised cervical screening programme 
for women aged 20-60 with an overall coverage of around 70%(7). Since 2008, there has also 
been a school-based vaccination programme targeting 12-13 year old girls, with an initial three 
year catch-up campaign for girls aged up to 18. Vaccination coverage has been high with 
sustained uptake of over 90% in the target population and 65% overall in the catch-up group 
(with variation according to age and whether in or out of school)(8),(9). Girls vaccinated as 
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part of catch-up have been entering the screening programme since 2010. Data linkage 
capabilities in Scotland, facilitated through a unique personal identifier, enable screening, 
cervical disease and vaccination data to be assessed. A national surveillance programme in 
Scotland was set up to assess the impact of HPV immunisation at a population level and has 
shown significant reductions amongst immunised women in HPV16 and 18, in HPV 31, 33 
and 45 as a result of cross-protection from the bivalent vaccine2, a reduction in high and low 
grade cervical abnormalities with immunisation9 and most recently early evidence of herd 
immunity in non-immunised women(10).  
 
The Scottish HPV Prevalence in Vaccinated women (SHEVa) projects are complementary to 
the surveillance programme, which uses a highly sensitive epidemiologically orientated HPV 
assay, in that they have been designed to provide information on the performance of clinically 
validated HPV assays in vaccinated women. The primary objective of the present study was to 
assess and compare the prevalence of HR-HPV (overall and HPV16 and/or 18) in young 
vaccinated women (and a demographically comparable group of unvaccinated women), as 
detected by three clinically validated HPV assays and to determine whether assays are affected 
differentially by vaccination. Secondary objectives included gaining insights into performance 
of clinically validated assays by assessing the relative burden of HPV16 and/or 18 and other 
‘HR-HPV’ and type specific prevalence according to cytological reporting category, and the 
effect of age at first dose of vaccine on HR-HPV detection by these assays.. Implications of the 
data for the provision of future cervical screening services are discussed. 
Materials and Methods  
Sample set and data linkage  
A national HPV epidemiology and surveillance programme was set up since 2009, to monitor 
the impact of the vaccine in the Scottish population. One aspect of this involved the yearly 
collection of 1000 anonymised residual liquid based cytology (LBC) samples from young 
women aged 20–21 years attending their first screening appointment from all (9) NHS 
cytopathology laboratories that serve the cervical screening programme.  Impact of vaccine on 
infection using this sample through application of a sensitive epidemiologically orientated 
assay has been reported previously(11). A subset of this wider surveillance collection was used 
for the SHEVa study. These were chosen by sequentially selecting all vaccinated samples 
available from the surveillance collection in 2012 (n=653) supplemented with samples from 
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the 2011 collection to make 1000. Similarly, for unvaccinated women, samples were chosen 
from 2012, 2011 and 2010 collections to make 1000.  Assuming an overall HPV prevalence of 
34% in young vaccinated women, 1000 samples from vaccinated women were tested with 1000 
age matched samples from unvaccinated women to enable us to estimate prevalence of HPV16 
and/or 18 to +/- 3%. All cytology laboratories were represented in the SHEVa collection to 
enable representativeness. 
All samples had been genotyped previously and linked to screening records and vaccination 
status with residual material stored in the Scottish HPV Archive 
(www.shine.mvm.ed.ac.uk/archive). Genotyping was originally performed using an 
analytically sensitive luminex-based assay – Optiplex HPV Genotyping kit (DiaMex Gmbh, 
Heidelberg, Germany) which resolves 24 HPV types including all types in IARC Group 1, 2A 
& 2B(12). Data on age at vaccination, dosage and cytology status were obtained via the 
Information Services Division (ISD) and Health Protection Scotland (HPS). Routine cytology 
classification was as per British Society for Clinical Cytology criteria. Cytology results were 
classed as negative (for any abnormality), low grade (borderline squamous changes, 
koilocytosis, and mild/low grade dyskaryosis) and high grade (which includes moderate 
dyskaryosis and worse)(13),(14).  
Ethics 
The East of Scotland Research Ethics Service has given generic approval to the Scottish HPV 
Archive as a Research Tissue Bank (REC Ref 11/AL/0174) for HPV related research on 
anonymised archive samples. The Scottish HPV Archive is also registered with NHS Lothian 
Tissue Governance and comes under its ‘safe haven’ for research using clinical samples. 
Samples were made available for the present project though application to the Archive Steering 
Committee (HPV Archive Application Ref 0017). 
HPV testing protocols 
All samples were subject to testing by three clinically validated assays: 1) RealTime High Risk 
HPV (rtHPV) assay (Abbott Molecular, Illinois, U.S.A.); 2) Aptima HPV (AHPV) assay 
(Hologic, Bedford, U.S.A) and 3) OnclarityTM HPV Assay (Becton Dickinson, NJ, U.S.A) 
according to manufacturer’s guidelines. rtHPV and Onclarity HPV assays are DNA based 
assays while AHPV is an RNA based assay. All three assays provide consensus results of 
positivity for HR-HPV if one of the following types is present: 16, 18, 31, 33, 35, 39, 45, 51, 
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52, 56, 58, 59, 66, 68. Furthermore, rtHPV provides concurrent genotyping of 16 and 18; 
Onclarity provides concurrent, individual typing of 16, 18, 31, 45, 51, 52, in addition to three 
groups of types: 33/58, 56/59/66, 35/39/68; and AHPV provides reflex testing for 16 and for 
18/45 as a duplex. The impact of three doses of vaccination on overall HR-HPV and on HPV16 
and/or 18 prevalence demonstrated by the assays was assessed. Samples negative for either 
HPV16 and/or 18 but positive for one of the other HR-HPVs were designated as ‘other HR-
HPV’.  
Statistical Analysis 
Prevalence and corresponding 95% confidence intervals (CI) were stratified by vaccination 
status and subsequently according to cytological reporting category. The differences in 
prevalence for each assay were assessed using a test of two proportions with an adjustment 
made for multiple comparisons, using a Bonferroni correction applied to the significance cut-
off point, due to the multiplicity of tests conducted (36 tests of proportions and 12 interaction 
tests giving the significant level, alpha=0.05/48=0.00104). 
Between-assay differences in HPV prevalence were conducted using a multi-level logistic 
regression model to account for repeated testing of the same sample with each assay. 
Comparison of the between-assay differences in vaccinated vs unvaccinated women were 
assessed by conducting a test of interaction. Possible effect modification linked with 
cytological status was also examined. Type specific prevalence beyond HPV16 and/or 18 was 
assessed via descriptive analysis of the five most prevalent types in vaccinated vs unvaccinated 
women stratified by underling cytology. Impact of age at first dose of vaccine on the odds of 
being infected with HR-HPV and HPV16 and/or 18 was assessed for all assays and according 
to underlying cytology. All statistical analysis was carried out using R version 3.1. 
Results 
Study population 
A total of 2000 samples were included the study, of which 993 were from unvaccinated and 
1007 from vaccinated women (the number of vaccinated samples increased by 7 due to 
subsequent updated linkage of vaccination records). Four samples were excluded due to the 
following reasons: <3 doses of vaccine (n=1), age >21 (n=2) or missing age information (n=1). 
A further 8 samples were excluded due to technically invalid test results. Thus, the final study 
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population included samples from 988 unvaccinated and 1000 vaccinated individuals. 
Characteristics of the population can be seen in Table 1. The median age of receipt of first dose 
of vaccine and age at screening, was 17 and 21 years respectively. Abnormal cytology was 
associated with samples from 26.7% unvaccinated and 19% vaccinated women. The 
proportions of non-negative cytology in the wider national surveillance sample set (n= 6918) 
was very similar (25.6%) although was slightly higher when compared to Scottish national 
screening data on females born in 1990-1992 (n= 54518) which was 19.8% (Palmer et al, 
submitted) 
HPV positivity 
Of the 1988 samples tested with the Optiplex HPV assay, 48.7% (95% CI: 46.5-50.9%) were 
positive for any HR-HPV. The clinically validated assays showed lower positivity, 39.1% 
(AHPV), 43.2% (Onclarity), 44.0% (rtHPV). No significant difference in positivity was found 
between rtHPV and Onclarity (p=0.193) but a significant difference between rtHPV and AHPV 
was observed (p<0.0001). 
Impact of vaccination on HR-HPV and HPV16 and/or 18 detected by clinically 
validated assays 
Overall HR-HPV prevalence was significantly lower in women who had been vaccinated 
(p<0.0001) with all assays, with positivity reducing by 11.6%, 12.5% and 15.1% for the rtHPV, 
Onclarity and AHPV, respectively. This equates to a reduction in positivity for any hr-HPV of 
23.2% and 25.2% for the rtHPV and Onclarity DNA assays, respectively, and 32.2% for the 
AHPV RNA assay (Table 2). The AHPV assay showed the greatest reduction between the 
vaccinated and unvaccinated groups when compared with the other assays (p<0.0001).  
As expected, reduction of HPV16 and/or 18 was highly significant for all assays (p<0.0001) 
with the prevalence in unvaccinated and vaccinated women being 21.4% and 5.0% for the 
rtHPV assay, 21.2% and 4.7% for the Onclarity assay and 19.8% and 4.5% for the AHPV assay 
(with no delineation between 18/45). No significant between-assay differences were observed 
for HPV 16 and/or 18 (p=0.813). 
When considering other HR-HPV, a small but insignificant increase was observed in the 
vaccinated group with all three clinically validated assays. The AHPV assay demonstrated a 
smaller difference between the unvaccinated and vaccinated groups, as compared to the other 
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two DNA based assays for the detection of other HR-HPV and AHPV was significantly 
different from the other two assays (p<0.0001).   
Impact of vaccination on HR-HPV and HPV16 and/or 18 according to underlying 
cytology  
As the number of women with high grade cytology was very small (21 in the unvaccinated 
group and 6 in the vaccinated group), this analysis focuses on women with either negative 
(n=1507) or low grade cytology (n=427).  
A total of 707 and 800 samples with negative cytology were present in the unvaccinated and 
vaccinated groups respectively. Significant reductions in HR-HPV and HPV16 and/or 18 
prevalence were observed in vaccinated women (p<0.0001 for all assays, Figure 1). No 
significant differences between the assays for the detection of HR-HPV (p=0.0044) and HPV16 
and/or 18 (p=0.37) were observed. Non-significant increases in other HR-HPV were observed 
for rtHPV (p=0.17) and Onclarity (p=0.36) whereas a non-significant reduction for other HR-
HPV was observed with AHPV (p=0.25).      
A total of 243 and 184 samples with low grade cytological abnormality were present in the 
unvaccinated and vaccinated groups respectively. The prevalence of HPV16 and/or 18 in 
unvaccinated and vaccinated groups reduced significantly from 36.1% to 9.8% for rtHPV, 
37.0% to 8.7% for Onclarity and 39.5% to 9.2% for AHPV (p<0.0001 for all assays). A highly 
significant (p<0.0001) increase in other HR-HPV types was also observed for all assays (Figure 
1). No significant difference between the assays for the detection of HR-HPV (p=0.186), HPV 
16/18 (p=0.122) or other HR-HPV (p=0.80) was observed in the group with low grade 
cytology.  
Impact of age at vaccination on prevalence of HR-HPV and HPV16 and/or 18  
Odds ratios (ORs) for infection with HR-HPV and HPV16 and/or 18 according to age at first 
dose of vaccine (ages 15/16, 17 and 18+) were calculated for each assay in the total population 
and according to underlying cytology (Table 3). Detection of HR-HPV or other HR-HPV, 
according to all assays was not affected by age at 1st dose of vaccine, whereas HPV16 and/or 
18 was less likely to be detected in girls vaccinated at a younger age (p for linear trend <0.00001 
for all assays).  
Comparison of type specific prevalence using clinically validated and epidemiological assay  
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Among the women with HR-HPV infection, type-specific HPV data (beyond HPV16 and/or 
18) was available via the Onclarity and epidemiological Optiplex tests, although the Onclarity 
can only provide resolution of 16, 18, 31, 45, 51, 52 with the remaining types detected as three 
groups: 56/59/66, 35/39/68 and 33/58. According to the Optiplex assay, HPV16 remained 
within the top 5 HPV types in vaccinated women overall irrespective of underlying cytology. 
However, this was not observed using the Onclarity assay where HPV16 did not feature in the 
top 5 for any cytology category in vaccinated women (Table 4a and b). Further, the most 
common type detected by the Optiplex and Onclarity assays differ when stratified by age at 
first dose of vaccination (Table 4c). For the Optiplex assay, HPV16, HPV59 and HPV56 were 
the most frequently detected types in girls vaccinated at 18, 17 and 15/16 respectively. 
Comparatively, application of the Onclarity assay showed the most common group 56/59/66 
as unchanged with age at first dose.   
Discussion 
HR-HPV infection reduced significantly in vaccinated women attending for cervical screening 
as measured by three clinically validated HPV assays which target both viral DNA and RNA. 
The reduction in HR-HPV in vaccinated women as measured by the AHPV assay was 
significantly higher than the reduction measured by the DNA-based assays (p<0.001). The 
AHPV has shown higher clinical specificity compared to DNA based assays in low grade triage 
and more recently, primary screening contexts(15),(16). It is feasible that the greater reduction 
associated with AHPV is due to exclusion of transient or clinically insignificant infection 
through amplification of an mRNA target. However, longitudinal follow-up relative to disease 
end points is required to demonstrate this. The data also show that the most common types in 
vaccinated women detected by Optiplex (epidemiologically orientated )assay were different to 
those detected by Onclarity (clinically validated) assay. This may reflect the difference in assay 
design (consensus PCR versus gene-specific type detection) which influences the assay’s 
ability to accurately detect multiple infections(17) and the fact that the epidemiological assay 
cut off is not calibrated to disease end-points. This re-emphasises the point that extrapolation 
of surveillance data to inform HPV based screening strategies should be performed with 
caution.   
Given the move to HPV primary screening, an understanding of the prevalence of infection at 
clinically relevant levels in vaccinated women will help inform the design of screening 
services. Figure 2 shows an overview of HPV positivity in the vaccinated (A) and unvaccinated 
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groups (B) according to each test with further stratification into the cytology categories. This 
provides preliminary insight into the management challenges of HPV primary screening in 
vaccinated populations. Using the rtHPV assay as an example, approximately 50% of the HPV 
positive unvaccinated women were associated with no cytological abnormality, whereas in 
vaccinated women this was approximately 60%.   
The optimal management of HPV positive infections in the era of primary HPV screening 
remains a challenge. There is consensus that triage of HPV positive women is required for 
management, but the method of triage is still a matter of debate. Cytology, HPV testing and/or 
partial genotyping for HPV16 and/or 18 alone or in combination have all been suggested(18). 
Our data indicate that the burden of HPV positive samples for any triage will be lower in 
vaccinated women using clinically validated assays (a reduction of 23-25% for the DNA based 
assays and 32% for the RNA based assay). Furthermore of the 32-38% of HR-HPV infections 
detected in vaccinated women only 4.5-5% were HPV16 and/or 18 positive, compared to 
around 20% which were HPV16 and/or 18 positive in unvaccinated women. As the impact on 
HPV16 and/or 18 in the present analysis was observed in the catch-up population, reduction of 
these types in the girls vaccinated as part of the routine programme will be greater. Indeed, 
even within the catch-up group, girls vaccinated at a younger age were significantly less likely 
to be infected with HPV16 and/or 18 (p<0.00001 for all assays). Therefore, the practicalities 
and success of triage of HPV positive women using HPV16 and/or 18 typing will be affected 
by the increasing number of vaccinated women who enter cervical screening programmes.   
When women with low-grade cytology results were assessed separately, all assays showed a 
significantly higher proportion of other HR-HPV in vaccinated compared with unvaccinated 
women (p<0.0001). This has implications when considering HPV triage of low grade smears 
in vaccinated women within existing cytology-based programmes. Given the established 
higher risk of HPV16 and/or 18, compared to other high-risk types for CIN2+ development, 
the positive predictive value of low grade triage following HPV testing may reduce(19),(20). 
One might speculate that the positive predictive value of abnormal cytology (alone) might also 
reduce, given that a greater proportion of low grade smears will be associated with lower risk 
types. This speculation is consistent with a recent analysis of Scottish national data which 
indicated that the abnormal predictive value and positive predictive value of cytology in 
vaccinated women has reduced(21).  
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Whether the aforementioned observations represent a true increase in other HR-HPV is 
debatable as the number of abnormal samples was relatively small and there was an overall 
reduction in the number of low grade abnormalities in vaccinated women, resulting in different 
denominators. Our observations are complementary to the findings in a similar age-matched 
cohort of 13-26 year-old women from two US primary care clinics by Kahn et al (2014)(22), 
where the prevalence of non-vaccine HPV types increased by 14.0% (60.8%–74.8%) for all 
participants and that this increase was significant in vaccinated (but not unvaccinated) 
participants.  A recent ecological modelling study suggested that co-existence of multiple HPV 
types is possible due to ‘patchy distribution’ of the more virulent types with less virulent 
types(23). The introduction of a vaccine with modest degree of cross-protection might result 
in eradication of non-vaccine types. However, we observed a higher level of non-vaccine types 
in women with low-grade abnormality and this would be consistent with the ‘competitive 
exclusion equilibrium’ described by Waters (2012), rather than a competitive co-existence 
equilibrium which was observed in the overall population.   
The observations are more likely to reconcile with the notion of unmasking, i.e. non HPV16 
and/or 18 types become more readily detected as a consequence of less competition for 
molecular resources within the assay. DNA amplification approaches which incorporate 
consensus primers, rather than type specific primers, might be expected to be particularly 
affected by this phenomenon and it was of note that the assays associated with higher increases 
in the overall population were the Optiplex and rtHPV assay, the two DNA assays that utilise 
consensus PCR.  Moreover, this unmasking phenomenon has been observed in an Australian 
post-vaccine surveillance study using simulated samples tested with a consensus primer 
approach(24). Recent data from another study within the Scottish primary screening population 
(PaVDaG) showed no overall decrease in the prevalence of HR-HPV associated with 
vaccination in women aged 20-24 using the cobas® HPV Assay (Roche, Basel, 
Switzerland)(25). In PaVDaG, where Cobas HPV is based on consensus primers, HPV 
positivity was detected in 45.3% and 47.6% of unvaccinated and vaccinated women 
respectively, although the prevalence of HPV16 and/or 18 was 15.2% and 4.7% respectively. 
Interestingly, the distribution of the other HR-HPV types is different depending on the assay 
used (Table 4c). HPV type 16 was the most common type detected by the Optiplex assay in the 
overall population whereas 56/59/66 was the most common grouping detected by Onclarity. This re-
emphasizes the fact that assays maybe affected differentially by vaccination. If the proportion 
of HPV16 and/or 18 infections in women attending for primary screening reduces, while other 
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types become more prevalent through unmasking, the PPV of an HPV positive result for 
significant disease may also reduce. Clearly, further studies are needed and this should be 
addressed through longitudinal follow-up of HPV infection in vaccinated women relative to 
disease.   
There are limitations to this study. Firstly, women were vaccinated as part of catch-up. An 
earlier Scottish epidemiological study of unvaccinated 11-18 years olds showed 12.6% of girls 
aged 15-18 were infected with HR- HPV, so some may have been exposed to HPV before 
vaccination(26).  Consequently the impact of vaccination when girls vaccinated aged 12-13 
enter the screening system will be different to the observations reported here. Secondly, we did 
not include all clinically validated assays (Arbyn et al(5))  and no signal (as opposed to target) 
amplification assays were assessed. Finally, we did not directly evaluate clinical performance 
of the assays in vaccinated women relative to disease endpoints in this study. Future plans to 
address this are in process, through linkage to clinical follow-up data as this is important for 
assessing clinical performance of these assays in vaccinated women. 
To conclude, while there will be less HR-HPV infection to manage in vaccinated women using 
clinically validated assays, the amount remaining may differ significantly according to assay 
chemistry. Potential unmasking of other HPV types, given the substantial reductions in HPV16 
and/or 18 and dominance of other HR-HPV, may have implications for both HPV and cytology 
based screening programmes. Clinical validation metrics designed to investigate the 
performance of established and new HPV assays which take into account the increasing 
influence of vaccination will be welcome, as will longitudinal data series which link HPV status 
in vaccinated women to long term disease outcomes. 
Acknowledgements  
The authors would like to acknowledge Hologic and BD for reagents, equipment and training 
to enable testing. This work made use of the Scottish HPV Archive, a resource for research 
(www.shine.mvm.ed.ac.uk/archive) setup through Programme Grant from the Chief Scientist 
Office of the Scottish Government (CZB/4/658). Thanks are also due to NRS Lothian 







1.  Drolet M, Bénard É, Boily M-C, Ali H, Baandrup L, Bauer H, et al. Population-level 
impact and herd effects following human papillomavirus vaccination programmes: a 
systematic review and meta-analysis. Lancet Infect Dis. 2015 May;15(5):565–80.  
2.  Kavanagh K, Pollock KGJ, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction 
and sustained high coverage of the HPV bivalent vaccine leads to a reduction in 
prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014 May 
27;110(11):2804–11.  
3.  Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. 
Assessment of herd immunity and cross-protection after a human papillomavirus 
vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 
2014 Oct;14(10):958–66.  
4.  Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of 
HPV-based screening for prevention of invasive cervical cancer: follow-up of four 
European randomised controlled trials. Lancet Lond Engl. 2014 Feb 8;383(9916):524–
32.  
5.  Arbyn M, Snijders PJF, Meijer CJLM, Berkhof J, Cuschieri K, Kocjan BJ, et al. Which 
high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin 
Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2015 May 1;  
6.  Choi YH, Chapman R, Gay N, Jit M. Potential overestimation of HPV vaccine impact 
due to unmasking of non-vaccine types: quantification using a multi-type mathematical 
model. Vaccine. 2012 May 14;30(23):3383–8.  
7.  http://www.isdscotland.org/health-topics/cancer/cervical-screening/.  
8.  HPV Immunisation Uptake Rates HPV Immunisation Programme – School Year 
2013/14 Publication date – 30 September 2014. http://www.isdscotland.org/health-
topics/child-health/publications/;  
9.  Pollock KGJ, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of 
low- and high-grade cervical abnormalities associated with high uptake of the HPV 
bivalent vaccine in Scotland. Br J Cancer. 2014 Oct 28;111(9):1824–30.  
10.  Cameron R, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, et al. Human 
papillomavirus prevalence and herd immunity after introduction of vaccination program, 
Scotland. Emerg Infect Dis. In press.  
11.  Kavanagh K, Sinka K, Cuschieri K, Love J, Potts A, Pollock KG, et al. Estimation of 
HPV prevalence in young women in Scotland; monitoring of future vaccine impact. 
BMC Infect Dis. 2013 Nov 5;13(1):519.  
12.  IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO 
HUMANS. http://monographs.iarc.fr/ENG/Monographs/vol100B/;  
14 
 
13.  Achievable standards, Benchmarks for reporting, and Criteria for evaluating cervical 
cytopathology. http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp01.html;  
14.  Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening 
Programme. http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.html;  
15.  Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, et al. The 
APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US 
or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer J Int 
Cancer. 2013 Jan 1;132(1):101–8.  
16.  Monsonego J, Hudgens MG, Zerat L, Zerat J-C, Syrjänen K, Smith JS. Risk assessment 
and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) 
DNA and mRNA testing in primary cervical cancer screening (the FASE study). 
Gynecol Oncol. 2012 Apr;125(1):175–80.  
17.  Mori S, Nakao S, Kukimoto I, Kusumoto-Matsuo R, Kondo K, Kanda T. Biased 
amplification of human papillomavirus DNA in specimens containing multiple human 
papillomavirus types by PCR with consensus primers. Cancer Sci. 2011 
Jun;102(6):1223–7.  
18.  Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VMH, Hesselink AT, Rozendaal L, et 
al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based 
cervical screening. Int J Cancer J Int Cancer. 2012 Feb 1;130(3):602–10.  
19.  Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The 
elevated 10-year risk of cervical precancer and cancer in women with human 
papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing 
in clinical practice. J Natl Cancer Inst. 2005 Jul 20;97(14):1072–9.  
20.  Thomsen LT, Frederiksen K, Munk C, Junge J, Iftner T, Kjaer SK. Long-term risk of 
cervical intraepithelial neoplasia grade 3 or worse according to high-risk human 
papillomavirus genotype and semi-quantitative viral load among 33,288 women with 
normal cervical cytology. Int J Cancer J Int Cancer. 2015 Jul 1;137(1):193–203.  
21.  Palmer TJ, Robertson C, Cuschieri K, Nicoll S, Pollock KGJ. Effect of HR-HPV 
immunisation on the performance of cervical cytology. In: OC12, p206. Sevilla, Spain; 
February 4th to 7th.  
22.  Kahn JA, Brown DR, Ding L, Widdice LE, Shew ML, Glynn S, et al. Vaccine-Type 
Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction. 
Pediatrics. 2012 Aug;130(2):e249–56.  
23.  Waters EK. Aggregation and competitive exclusion: explaining the coexistence of 
human Papillomavirus types and the effectiveness of limited vaccine conferred cross-
immunity. Acta Biotheor. 2012 Dec;60(4):333–56.  
24.  Cornall AM, Phillips S, Cummins E, Garland SM, Tabrizi SN. In vitro assessment of 
the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of 
non-vaccine HPV types: implications for post-vaccine surveillance studies. J Virol 
Methods. 2015 Mar;214:10–4.  
15 
 
25.  Stanczuk G, Baxter G, Currie H, Foster A, Cuschieri K, Wilson A. Effect of catch up 
vaciantion on HPV prevalence in routine cervical screening. In: OC3-7, p157. Sevilla, 
Spain; 2015.  
26.  O’Leary MC, Sinka K, Robertson C, Cuschieri K, Lyman R, Lacey M, et al. HPV type-
specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year 






    Cytology grade (N) 
Age at 




grade Negative Unsatisfactory Total  
<20 or 20 
Unvaccinated  12 138 494 12 656 
vaccinated- age 15   3 20 0 23 
vaccinated- age 16 3 98 336 4 441 
vaccinated- age 17   26 197 2 225 
vaccinated- age 18 1 24 141 1 167 
vaccinated- age 19   5 13   18 
21 
Unvaccinated  9 105 213 5 332 
vaccinated- age 16   2 10   12 
vaccinated- age 17 1 23 65 3 92 
vaccinated- age 18 1 3 12   16 
vaccinated- age 19     6   6 


















rtHPV 49.8 (46.7-52.9) 38.2 (35.2-41.3) -11.6 < 0.0001 
Onclarity 49.5 (46.4-52.6) 37.0 (34.1-40.0) -12.5 < 0.0001 
AHPV 46.7(43.6- 49.8) 31.6 (28.8-34.5) -15.1 < 0.0001 
HPV16 and/or 18 
rtHPV 21.4 (18.9-24.0) 5.0 (3.8- 6.5) -16.4 < 0.0001 
Onclarity 21.1 (18.6-23.7) 4.7 (3.6-6.2) -16.4 < 0.0001 
AHPV 19.8 (17.5-22.4) 4.5 (3.4-6.0) -15.3 < 0.0001 
Other HR-HPV 
rtHPV 28.4  (25.7-31.3) 33.2 (30.4-36.2) +4.8 0.024 
Onclarity 28.4  (25.7-31.3) 32.3 (29.5-35.3) +3.9 0.068 
AHPV 26.8 (24.2-29.7) 27.1 (24.4-29.9) +0.3 0.929 








HPV outcome Assay 
 











16 and/or 18 rtHPV 15/16 1 - - <0.0001 
  17 2.716 1.166 6.654  
  18+ 7.538 3.483 17.742  
  Cytology Negative 1 - -  
  Cytology Low 3.62 1.887 6.819  
16 and/or 18 Onclarity 15/16 1 - - <0.0001 
  17 3.257 1.386 8.24  
  18+ 7.111 3.151 17.627  
  Cytology Negative 1 - -  
  Cytology Low 3.262 1.657 6.254  
16 and/or 18 AHPV 15/16 1 - - <0.0001 
  17 2.521 1.065 6.236  
  18+ 6.449 2.922 15.365  
  Cytology Negative 1 - -  
  Cytology Low 3.75 1.916 7.208  
Other HR-HPV rtHPV 15/16 1 - - 0.143 
  17 0.983 0.708 1.362  
  18+ 0.748 0.505 1.099  
  Cytology Negative 1 - -  
  Cytology Low 6.992 4.932 10.025  
Other HR-HPV 
Onclarity 15/16 1 - - 0.108 
  17 0.943 0.676 1.313  
  18+ 0.724 0.485 1.069  
  Cytology Negative 1 - -  
  Cytology Low 7.612 5.356 10.945  
Other HR-HPV AHPV 15/16 1 - - 0.395 
  17 1.089 0.766 1.545  
  18+ 0.835 0.547 1.26  
  Cytology Negative 1 - -  
  Cytology Low 8.079 5.699 11.552  






A. Optiplex HPV  
 
B. Onclarity HPV 
C. Age at 1st dose of vaccine 
 
Table 4: Five most common types in unvaccinated and vaccinated women stratified by cytology 
category using the Optiplex (A) and Onclarity assays (B). The most common HR-HPV types detected 





Total population Cytology Negative Cytology Low grade 
Unvaccinated  Vaccinated  Unvaccinated  Vaccinated  Unvaccinated  Vaccinated  
16 52 16 16 16 52 
52 56 51 59 56 56 
56 51 52 51 52 51 
51 16 56 56 59 66 
66 59 18 52 66 16 
Total population Cytology Negative Cytology Low grade 
Unvaccinated  Vaccinated  Unvaccinated  Vaccinated  Unvaccinated  Vaccinated  
56/59/66 56/59/66 16 56/59/66 56/59/66 56/59/66 
16 51 56/59/66 33/58 16 51 
35/39/68 35/39/68 33/58 35/39/68 35/39/68 35/39/68 
33/58 33/58 35/39/68 52 51 52 
31 52 31 51 52 33/58 
Age at 1st 
dose of 
vaccine  
Total population Cytology Negative Cytology Low grade 
 Optiplex  Onclarity Optiplex  Onclarity Optiplex  Onclarity 
15-16 56 56/59/66 59 56/59/66 56 56/59/66 
17 16 56/59/66 16 56/59/66 51 56/59/66 
18 16 56/59/66 16 56/59/66 16 56/59/66 
20 
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Figure 1: Positivity for Overall HR-HPV (top), HPV16 and/or 18 (middle) and other HR-HPV 





Figure 2A: Overview of HPV status in vaccinated women according to assay stratified by 
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Figure 2B: Overview of HPV status in unvaccinated women according to assay, stratified by 
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50.6 % (499) 
Cytology negative 
91.2% (95% CI- 88.4, 93.4)
N=455
Cytology low grade
6.8% (95% CI- 4.9, 9.3)
N=34
Cytology high grade
0%  (95% CI- 0, 0.8)
Cytology unsatisfactory
0.02%  (95% CI- 0.01, 0.04)
N=10
HR HPV positive 
49.4 % (489)
Cytology negative 
51.7% (95% CI- 47.3, 56.1)
N=252
Cytology low grade
42.6% (95% CI- 38.3, 47)
N=209
Cytology high grade
4.3%  (95% CI- 2.8, 6.4)
N=21
Cytology unsatisfactory







Table S1: HPV prevalence in unvaccinated and vaccinated women detected by HPV assays 
stratified by cytology grade.  
 
 














Negative Optiplex 43.2 (39.7-47.0) 33.4 (30.2-36.7) -9.8 <0.0001 
 rtHPV 36.6 (33.1–40.3) 28 (25.0-31.2) -3.7 0.0004 
 Onclarity 35.7 (32.2-39.2) 26.8 (23.8-29.9) -8.9 0.0002 
 AHPV 32.7 (29.3-36.2) 21.6 (18.9-24.6) -11.1 <0.0001 
Low Optiplex 84.8 (79.7-88.7) 80.4 (74.1-85.5) -4.4 0.294 
 rtHPV 84 (78.8-88) 79.3 (72.9-84.6) -4.7 0.272 
 Onclarity 86 (81.0-89.8) 78.8 (72.3-84.1) -7.2 0.067 
 AHPV 83.1(77.9-87.3) 73.9 (67.1-79.7) -9.2 0.027 
HPV16 
and/or 18 
Negative Optiplex 25.7 (22.7-29.1) 10.1 (8.2-12.4) -15.6 <0.0001 
 rtHPV 14.9 (12.4- 17.7) 3.5 (2.4-5.0) -11.4 <0.0001 
 Onclarity 13.9 (11.5-16.6) 3.4 (2.3-4.9) -10.5 <0.0001 
 AHPV 11.7 (9.6- 14.3) 3.1 (2.1-4.6) -8.6 <0.0001 
Low Optiplex 49 (42.8-55.2) 19.0 (14.0-25.3) -30 <0.0001 
 rtHPV 36.2 (30.4- 42.4) 9.8 (6.3-14.9) -26.4 <0.0001 
 Onclarity 37.0 (31.2-43.3) 8.7 (5.4-13.7) -28.3 <0.0001 
 AHPV 39.5 (33.6-45.8) 9.2 (5.8-14.3) -30.3 <0.0001 
Other HR-
HPV 
Negative Optiplex 17.5 (14.9-20.5) 23.25 (20.5-26.3) 10.8 0.007 
 rtHPV 21.8 (18.9-25.0) 24.5 (21.6-27.6) 2.7 0.236 
 Onclarity 21.8 (18.9-25.0) 23.4 (20.6-26.4) 1.6 0.499 
 AHPV 20.9 (18.1-24.1) 18.5 (16.0-21.3) -2.4 0.262 
Low Optiplex 35.8 (30.0-42.0) 61.4 (54.2-68.1) 25.6 <0.0001 
 rtHPV 47.7 (41.5-54.0) 69.6 (62.6-75.8) 21.8 <0.0001 
 Onclarity 49.0 (42.8-55.2) 70.1 (63.1-76.3) 21.1 <0.0001 
 AHPV 43.6 (37.5-49.9) 64.7 (57.5-71.2) 21.1 <0.0001 
